Prosensa Therapeutics, a Dutch biopharmaceutical company focused on RNA-modulating therapeutics for rare diseases with high unmet need, has hired Larry Bell as its Vice President of Regulatory Affairs. Dr Bell will be based in the US.
Dr Bell has more than 18 years’ experience in running regulatory affairs for world-leading pharmaceutical companies including Merck, Bristol-Myers Squibb, Aventis and Amgen. Before setting up his own consultancy, in his most recent role he was Vice President and Global Head of Regulatory Affairs at GE Healthcare.
At Prosensa, Dr Bell will be overseeing the company’s global regulatory activities and given the ground-breaking nature of Prosensa’s exon-skipping therapies and the need to ensure an efficient route to patients, he will also be instrumental in developing appropriate regulatory strategies and effective relationships with the relevant authorities in US, Europe and Japan. Commenting on his appointment, Dr Bell said: ‘This is a key time to be joining the Prosensa team. As the orphan drugs space grows in size and scope, there are many regulatory considerations that need to be addressed in order for new drugs to reach the patients that need them. I look forward to helping progress Prosensa’s cutting-edge therapies through the regulatory process.’
